
|Videos|March 2, 2017
Dr. Tagawa on Next Steps for Taxanes in Prostate Cancer
Author(s)Scott T. Tagawa, MD
Scott T. Tagawa, MD, Weill Cornell Medicine, discusses next steps for taxanes following the TAXYNERGY trial in prostate cancer.
Advertisement
Scott T. Tagawa, MD, Weill Cornell Medicine, discusses next steps for taxanes following the TAXYNERGY trial in prostate cancer.
Although these results do not suggest changing from one particular taxane to the other, TAXYNERGY validated androgen receptor (AR) translocation as a mechanism of action of taxane chemotherapy, says Tagawa.
The next step is to use biomarkers to look at drug-target engagement in clinical trials, says Tagawa, which would hopefully determine the most effective AR plus a taxane combination for patients.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 1/25
2
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5



































